ALOXI OFFERS IMPROVED CINV CONTROL FOR PATIENTS WITH BREAST CANCER
Because female gender and younger age are significant risk factors for CINV, a retrospective subset
analysis of female patients with breast cancer was conducted using pooled data from 2 identically
designed, multicenter, randomized, double-blind, comparative phase III studies (n=754).1-3
- Of a total of 754 patients, 476 females with breast cancer were included in the subset analysis (mean age=52 yrs).
- Patients received a single IV dose of ALOXI (0.25 mg), ondansetron (32 mg), or dolasetron (100 mg) 30 minutes prior to chemotherapy.
- Complete response rates for ALOXI were higher during the acute phase and
superior during the delayed phase and overall compared with ondansetron or dolasetron (p=0.01).1
GREATER FREEDOM FROM NAUSEA AND VOMITING
MORE PATIENTS TREATED WITH ALOXI WERE NAUSEA-FREE IN THE DAYS FOLLOWING CHEMOTHERAPY
- The CINV that persists even after antiemetic treatment may impact a patient’s quality of life and daily functioning.4
- Significantly more patients receiving ALOXI were nausea-free in the days following chemotherapy than those receiving ondansetron or dolasetron, including days 2 and 3 following chemotherapy, when patients tend to suffer the worst nausea (p<0.05).4
- Additionally, more patients were emesis-free in the ALOXI group than those treated with ondansetron or dolasetron during the acute phase, delayed phase, and overall (p=0.01).4
Click here to view the results of ALOXI vs. Ondansetron in Highly Emetogenic Chemotherapy.
References
- Hudis CA, Hainsworth JD, Perez EA, Macciocchi A. Palonosetron (PALO) is more effective than ondansetron/dolasetron (OND/DOL) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients with breast cancer (BC): combined results of 2 phase III trials. Breast Cancer Res Treat. 2003;82(suppl 1):1-184. Abstract 635.
- Eisenberg P, Figueroa-Vadillo J, Zamora R, et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer. 2003;98:2473-2482.
- Gralla R, Lichinitser M, Van der Vegt S, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol. 2003;14:1570-1577.
- Grunberg SM, Hansen M, Deuson R, Mavros P. Incidence and impact of nausea/vomiting with modern antiemetics: perception vs reality. Proc Am Soc Clin Oncol. 2002;21:250a. Abstract 99